Boston, MA 08/13/2014 (wallstreetpr) – Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has announced the pricing of $300 million of 2% convertible notes that are due in 2019. The pharmaceutical company has also availed an option for initial purchasers to purchase an additional $45 million aggregate principal amount to cover for any form of over-allotments. The conversion rates of the notes stands at 24.2866 shares of Aegerion Pharmaceuticals common stock for every $1,000 principal amount notes, equivalent to initial conversion price of approximately $41.175 per share of common stock.
Offering To Close On Friday
The conversion rate represents a 35% premium on the company’s closing stock price of $30.50 as of Monday August 11. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has also stated that the conversion rate may be subject to adjustment during distribution of dividends or stock splits. The company plans to settle conversions of the convertible notes by delivering its common stock. The transaction is set to close on August 15, 2012 subject to customary closing conditions.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has also entered into a privately negotiated convertible note hedge transactions with initial purchasers a move that is expected not to affect dilution or offset any form of cash payment.
Uses of Net Proceeds
The company has also entered a similar transaction with hedge counterparties. Initial purchasers have also been given’ the option of exercising the option of purchasing additional convertible notes. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) plans to enter into addition transactions with hedge counterparties on warrant transactions and additional note hedge.
Net proceeds from the offering, as well as the entrance into warrant transactions, are to be used to bolster Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s working capital as well as cater for other general corporate expenses. Part of the money could be used to finance possible acquisition or future investments in businesses technologies or for the repurchase of approximately $35 million outstanding common stock.
